Atrial Myxoma Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Atrial Myxoma
Atrial myxoma is a rare, non-cancerous heart tumor that can cause serious complications if left untreated. While diagnosis can be daunting, effective treatments are available. TheDrugClub is dedicated to helping you manage the costs associated with your care, ensuring you have access to essential medications and treatments without financial strain.
Atrial myxoma is the most common type of primary heart tumor, yet it remains relatively rare. This benign (non-cancerous) growth typically develops in the left upper chamber of the heart, known as the left atrium. While not malignant, an atrial myxoma can still pose significant health risks. Its presence can obstruct blood flow through the heart, causing symptoms like shortness of breath, dizziness, fainting, and chest pain. Pieces of the tumor can also break off and travel through the bloodstream (embolize), potentially leading to a stroke or damage to other organs.
Diagnosing atrial myxoma often involves an echocardiogram, a non-invasive ultrasound of the heart. Further imaging tests like MRI or CT scans may also be used to confirm the diagnosis and assess the tumor's size and location. Once identified, the primary treatment for atrial myxoma is surgical removal. This operation is typically highly successful and curative, preventing future complications. While surgery is the definitive treatment, patients may require medications both before and after the procedure. These could include drugs to manage any associated symptoms like irregular heart
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.